Monday, June 30, 2025

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1


 OSAKA, Japan & CAMBRIDGE, Mass. 

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with Primary Immunodeficiency1

U.S. Commercialization of GAMMAGARD LIQUID ERC Projected to Begin in 2026

Company Announces Future Manufacturing Discontinuation End Date for Takeda's First-Generation Low-IgA Product, A Freeze-Dried Formulation in Company’s Differentiated Immunoglobulin Portfolio of Ready-to-Use Liquids2

(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administration burden for patients and their health care providers by eliminating the need for reconstitution and can be administered intravenously or subcutaneously.1


“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the lowest IgA content of any ready-to-use liquid immunoglobulin therapy, and can be administered intravenously or subcutaneously,” said Kristina Allikmets, senior vice president and head of Research & Development for Takeda’s Plasma-Derived Therapies Business Unit. “GAMMAGARD LIQUID ERC uses the same state-of-the-art manufacturing process as our other ready-to-use liquid immunoglobulin formulations and is aligned with our forward-looking strategy to prioritize reliable supply while offering a broad range of immunoglobulin therapies to address varied patient needs.”


With this approval, Takeda continues to be the only manufacturer of IG therapy with low IgA content less than or equal to 2 µg/mL in a 10% solution.1 It is anticipated that commercialization of GAMMAGARD LIQUID ERC will begin in the U.S. in 2026, followed by the European Union in 2027, where GAMMAGARD LIQUID ERC is approved by the European Medicines Agency (EMA) as DEQSIGA®.3 The timeline to commercial launch is consistent with the time it takes to ramp up manufacturing and supply for plasma-derived therapies.


In parallel to this approval, and after thorough analysis, Takeda has decided to discontinue GAMMAGARD S/D [Immune Globulin Intravenous (Human)] IgA less than 1 µg/mL in a 5% solution, the company’s first-generation low IgA product.2 As the only lyophilized (freeze-dried) preparation in Takeda’s IG portfolio, GAMMAGARD S/D uses a different, older manufacturing process. For GAMMAGARD S/D, this process is no longer able to reliably meet the future needs of the patient community. Therefore, Takeda has informed the FDA and other health authorities that manufacturing of GAMMAGARD S/D will be discontinued at the end of December 2027. Beyond that date, Takeda intends to maintain GAMMAGARD S/D inventory until it is depleted or expired.


“We understand the impact that this news may have on patients who currently rely on GAMMAGARD S/D for their treatment,” said Kristina Allikmets. “We are communicating this information now to allow time for patients to work closely with their health care teams to develop alternative treatment plans.”


About GAMMAGARD LIQUID ERC

GAMMAGARD LIQUID ERC is a ready-to-use liquid immunoglobulin therapy with an IgA content of less than or equal to 2 µg/mL in a 10% solution to be administered intravenously or subcutaneously. It is indicated in the United States as replacement therapy for primary immunodeficiency (PI) in people two years of age and older.1


GAMMAGARD LIQUID ERC shares its manufacturing process with GAMMAGARD LIQUID [Immune Globulin Infusion (Human)], with the modification of parameters in a single process step to improve IgA reduction. This enhanced removal capability (ERC) results in a product with IgA less than or equal to 2 µg/mL in a 10% solution.1


While GAMMAGARD LIQUID ERC is not indicated specifically for IgA sensitivity in people with primary immunodeficiency, it may be an appropriate option for them based on their physician’s clinical judgment. GAMMAGARD LIQUID ERC is contraindicated in patients with a history of severe systemic hypersensitivity or anaphylactic reactions to the product. It also carries warnings and precautions regarding the potential for severe hypersensitivity reactions, including in patients who have previously tolerated immune globulin products. Despite containing low levels of IgA (≤2 µg/mL in a 10% solution), the risk of anaphylaxis remains.1


About GAMMAGARD S/D

GAMMAGARD S/D is lyophilized (freeze-dried) immunoglobulin therapy with IgA content less than 1 µg/mL in a 5% solution for intravenous use only. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older. GAMMAGARD S/D is also indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell CLL, for the treatment of adult patients with chronic immune thrombocytopenic purpura (ITP) to increase platelet count and to prevent and/or to control bleeding, and for the prevention of coronary artery aneurysms associated with Kawasaki syndrome in pediatric patients.2


About Primary Immunodeficiency (PI)

Primary immunodeficiency (PI) is a group of more than 550 rare and chronic disorders, where a part of the body’s immune system is missing or does not function the way it should.4 These conditions result from genetic mutations, which are usually inherited.5 The symptoms of PI vary and can include frequent and/or persistent infections and unusual autoimmunity, often leading to prolonged periods of misdiagnosis despite consultations with multiple specialists.6 In the United States, PI affects about 1 in 1,200 people.7


GAMMAGARD LIQUID ERC, GAMMAGARD LIQUID and GAMMAGARD S/D U.S. Important Safety Information


WARNING: THROMBOSIS


Thrombosis may occur with immune globulin (IG) products, including GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC and GAMMAGARD S/D. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.

For patients at risk of thrombosis, administer GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC and GAMMAGARD S/D at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.

Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

WARNING: RENAL DYSFUNCTION and ACUTE RENAL FAILURE


Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products, including GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC and GAMMAGARD S/D. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC and GAMMAGARD S/D do not contain sucrose.

Contraindications


GAMMAGARD LIQUID is contraindicated in patients with a history of anaphylactic or severe systemic hypersensitivity reactions to human IG, and IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG. Anaphylaxis has been reported with intravenous (IV) use of GAMMAGARD LIQUID.

GAMMAGARD LIQUID ERC and GAMMAGARD S/D are contraindicated in patients with a history of anaphylactic or severe systemic hypersensitivity reactions to the administration of GAMMAGARD LIQUID ERC and GAMMAGARD S/D.

Warnings and Precautions


Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. Severe hypersensitivity reactions and anaphylactic reactions with a fall in blood pressure have occurred in patients receiving GAMMAGARD S/D, including patients who tolerated previous treatments with GAMMAGARD S/D, even though it contains low levels of IgA. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis.


Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with IV use of IG products, especially those containing sucrose. Acute renal failure has been reported in association with GAMMAGARD LIQUID and GAMMAGARD S/D. Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and consider lower, more frequent dosing. If renal function deteriorates, consider discontinuation.


Hyperproteinemia, increased serum viscosity, and hyponatremia may occur. It is critical to distinguish true hyponatremia from pseudohyponatremia because certain treatments may lead to volume depletion, a further increase in serum viscosity, and a predisposition to thromboembolic events.


Thrombosis: Has been reported to occur following treatment with IG products and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.


Aseptic Meningitis Syndrome: Has been reported with use of IG. Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae. The syndrome usually begins within several hours to two days following IG treatment


Hemolysis: GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC, and GAMMAGARD S/D contain blood group antibodies, which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing.


Transfusion-Related Acute Lung Injury: Non-cardiogenic pulmonary edema has been reported with IV-administered IG, including GAMMAGARD LIQUID. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.


Transmittable Infectious Agents: Because GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC, and GAMMAGARD S/D are made from human plasma, they may carry a risk of transmitting infectious agents (e.g., viruses, other pathogens). No confirmed cases of viral transmission or variant Creutzfeldt-Jakob disease (vCJD) have been associated with GAMMAGARD LIQUID.


Interference with Lab Tests: False positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.


Alterations in serum sodium levels (i.e., acute hypernatremia, pseudohyponatremia) may occur with GAMMAGARD S/D. In patients on a low sodium diet, calculate the amount of sodium from GAMMAGARD S/D when determining dietary sodium intake.


Adverse Reactions


GAMMAGARD LIQUID


IV administration: The serious adverse reaction seen during IV clinical trials was aseptic meningitis. The most common adverse reactions observed in ≥5% of patients in clinical trials were headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur.


Subcutaneous administration: The most common adverse reactions observed in ≥5% of patients in clinical trials were infusion site (local) event (rash, erythema, edema, hemorrhage, and irritation), headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, and pain in extremity.


GAMMAGARD LIQUID ERC


The safety of GAMMAGARD LIQUID ERC in patients with primary humoral immunodeficiency (PI) is supported by two clinical studies conducted on GAMMAGARD LIQUID. No clinical studies have been conducted using GAMMAGARD LIQUID ERC.


IV administration: The most common adverse reactions observed in ≥5% of patients in study 1 were headache, fatigue, pyrexia, chills, nausea, pain in extremity, diarrhea, migraine, vomiting, dizziness, urticaria, cough, asthma, oropharyngeal pain, infusion site extravasation, arthralgia, rash, myalgia, pruritis, and cardiac murmur.


Subcutaneous administration: The most common adverse reactions observed in ≥5% of patients in study 2 were infusion site (local) event, headache, pyrexia, fatigue, heart rate increased, abdominal pain upper, vomiting, arthralgia, nausea, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous ulcer, migraine, oropharyngeal pain, and pain in extremity.


GAMMAGARD S/D


The most common adverse reactions observed in ≥5% of clinical trial patients during or within 48 hours of infusion were headache, nausea, chills, fatigue, pyrexia, upper abdominal pain, diarrhea, back pain, infusion site pain, hyperhidrosis, and flushing.


The most serious adverse reactions reported postmarketing include renal failure, thrombotic events (myocardial infarction, cerebrovascular accidents, and pulmonary embolism), anaphylactic shock, aseptic meningitis, and hemolysis.


Drug Interactions


Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).


For Full U.S. Prescribing Information for GAMMAGARD LIQUID, please visit: https://www.shirecontent.com/PI/PDFs/GAMLIQUID_USA_ENG.pdf


For Full U.S. Prescribing Information for GAMMAGARD LIQUID ERC, please visit: https://content.takeda.com/?contenttype=PI&product=GAM&language=ENG&country=USA&documentnumber=2


For Full U.S. Prescribing Information for GAMMAGARD S/D, please visit: https://www.shirecontent.com/PI/PDFs/GGSD_USA_ENG.pdf


For European Union Summary of Product Characteristics for DEQSIGA, please visit: https://www.ema.europa.eu/en/medicines/human/EPAR/deqsiga


About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.


Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.


The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.


Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


References


____________________________

1 GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution U.S. Prescribing Information.


2 GAMMAGARD S/D [Immune Globulin Intravenous (Human)] IgA less than 1 µg/mL in a 5% solution U.S. Prescribing Information.


3 European Medicines Agency. Deqsiga 100 mg/mL solution for infusion Summary of Product Characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/deqsiga


4 Immune Deficiency Foundation. Living With Primary Immunodeficiency. Accessed June 2025. Available at: https://primaryimmune.org/living-primary-immunodeficiency.


5 Center for Disease Control and Prevention. About Primary Immunodeficiency (PI). Accessed June 2025. Available at: https://www.cdc.gov/primary-immunodeficiency/about/index.html.


6 Immune Deficiency Foundation. Understanding Primary Immunodeficiency. Accessed June 2025. Available at: https://primaryimmune.org/understanding-primary-immunodeficiency.


7 Kobrynski L, Powell RW, Bowen S. J Clin Immunol. 2014;34(8):954-961.


 


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250628336756/en/



Permalink

https://www.aetoswire.com/en/news/3006202547655


Contacts

Media Contacts:

U.S. Media

Taryn Corbino

Taryn.Corbino@Takeda.com

+1 (781) 915-9223


International Media

Kristine Kelly

Kristine.Kelly@takeda.com

+41 445551917


 

Thales 2025 Global Cloud Security Study Reveals Organizations Struggle to Secure Expanding, AI-Driven Cloud Environments

 MEUDON, France - Monday, 30. June 2025 AETOSWire 



52% report AI security spending is displacing traditional security budgets

55% report cloud environments are more complex to secure than on-premises infrastructure

Enterprises now use an average of 85 SaaS applications, contributing to security tool sprawl

 


(BUSINESS WIRE) -- Thales, a global leader in technology and cybersecurity, today released the findings of its 2025 Cloud Security Study conducted by S&P Global Market Intelligence 451 Research, revealing that AI-specific security has rapidly emerged as a top enterprise priority, ranking second only to cloud security. Over half (52%) of respondents said they are prioritizing AI security investments over other security needs, signaling a shift in how organizations are allocating budgets in response to the accelerated adoption of AI. This year’s research captures perspectives on cloud security challenges from nearly 3,200 respondents in 20 countries across a variety of seniority levels.


Cloud remains at the forefront of security considerations


Cloud is now an essential part of modern enterprise infrastructure, but many organizations are still building the skills and strategies needed to secure it effectively. The variability of controls across cloud providers, combined with the distinct mindset required for cloud security, continues to challenge security teams. This pressure is only increasing as AI initiatives drive more sensitive data into cloud environments, amplifying the need for robust, adaptable protections.


This year’s Thales Cloud Security Study confirms that cloud security remains a top concern for enterprises worldwide. Nearly two-thirds (64%) of respondents ranked it among their top five security priorities, with 17% identifying it as their number one. Security for AI, a new addition to the list of spending priorities this year, ranked second overall, highlighting its growing importance. Despite sustained investment, cloud security remains a complex, persistent challenge that goes beyond technology to include staffing, operations, and the evolving threat landscape.


“The accelerating shift to cloud and AI is forcing enterprises to rethink how they manage risk at scale,” Sebastien Cano, Senior Vice President, Cyber Security Products at Thales, said. “With over half of cloud data now classified as sensitive, and yet only a small fraction fully encrypted, it’s clear that security strategies haven’t kept pace with adoption. To remain resilient and competitive, organizations must embed strong data protection into the core of their digital infrastructure.”


The average number of public cloud providers per organization has risen to 2.1, with most also maintaining on-prem infrastructure. This growing complexity is driving security challenges with 55% of respondents reporting that cloud is harder to secure than on-prem, a 4-percentage-point increase from last year. As organizations expand through growth or M&A, they’re also seeing a surge in SaaS usage, now averaging 85 applications per enterprise, complicating access control and data visibility.


This complexity extends to security operations, with many teams struggling to align policies across varied platforms. The study found that 61% of organizations use five or more tools for data discovery, monitoring, or classification, and 57% use five or more encryption key managers.


Attacks target cloud resources with human error remaining a top vulnerability


Cloud infrastructure is a prime target for attackers as organizations continue to struggle with securing increasingly complex environments. According to the 2025 Thales Cloud Security Study, four of the top five most targeted assets in reported attacks are cloud-based. The rise in access-based attacks, as reported by 68% of respondents, underscores growing concerns around stolen credentials and insufficient access controls. Meanwhile, 85% of organizations say at least 40% of their cloud data is sensitive, yet only 66% have implemented multifactor authentication (MFA), leaving critical data exposed. Compounding the issue, human error remains a major contributing factor in cloud security incidents, from misconfigurations to poor credential management.


“A rising number of respondents report challenges in securing their cloud assets, an issue that is further amplified by the demands of AI projects that often operate in the cloud and require access to large volumes of sensitive data,” Eric Hanselman, Chief Analyst at S&P Global Market Intelligence 451 Research, said. “Compounding this issue, four of the top five targeted assets in reported attacks are cloud-based. In this environment, strengthening cloud security and streamlining operations are essential steps toward enhancing overall security effectiveness and resilience.”


For more information, please download the full report and join our webinar hosted by Eric Hanselman, Chief Analyst at S&P Global Market Intelligence 451 Research.


About Thales


Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.


The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.


Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.


PLEASE VISIT


Thales Group


Cloud Protection & Licensing Solutions | Thales Group


Cybersecurity Solutions | Thales Group


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250630070161/en/



Permalink

https://www.aetoswire.com/en/news/3006202547644


Contacts

PRESS


Thales, Media Relations

Security & Cybersecurity

Marion Bonnet

+33 (0)6 60 38 48 92

marion.bonnet@thalesgroup.com

SBC Medical added to membership of Russell 3000® Index

 IRVINE, Calif. - Saturday, 28. June 2025 AETOSWire Print 



(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution.


Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.


Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.


Fiona Bassett, CEO of FTSE Russell, An LSEG Business, comments:

“The Russell indexes have continuously adapted to the evolving dynamic US economy, and it’s crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.”


For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.


About SBC Medical


SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.


For more information, visit https://sbc-holdings.com/


About FTSE Russell, an LSEG Business


FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.


FTSE Russell is wholly owned by London Stock Exchange Group.


For more information, visit FTSE Russell.


Forward-Looking Statements


This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250608244276/en/



Permalink

https://www.aetoswire.com/en/news/2806202547638


Contacts

SBC Medical Group Holdings Incorporated (Asia)

Hikaru Fukui / Head of Investor Relations E-mail: ir@sbc-holdings.com


ICR LLC (In the US)

Bill Zima / Managing Partner Email: bill.zima@icrinc.com

Jadwa leads a USD 50 million investment round in PetroApp



 Jadwa Investment, a leading investment management and advisory firm in the Middle East, today announced it has led a USD 50 million investment round in PetroApp, Saudi Arabia’s leading fuel management platform, through its flagship blind-pool vehicle, Jadwa GCC Diversified Private Equity Fund. Bunat Ventures, a regional venture capital firm, also participated in the round.

Founded in 2018, PetroApp is Saudi Arabia’s first independent provider of digital fuel payment and fleet management solutions. It is transforming vehicle operations by eliminating cash transactions, reducing fraud, and improving cost control for corporate and government fleets. Beyond fuel, PetroApp also enables access to ancillary services—such as car washes, oil changes, tire and battery replacements—via a seamless, fully cashless platform.

Today, PetroApp manages over 500,000 vehicles for 10,000+ corporate clients through a network of more than 5,000 fuel stations across Saudi Arabia, Egypt, Thailand, and Nigeria, as the company continues its international expansion. It was recently accredited by the Expenditure and Projects Efficiency Authority (EXPRO) as a qualified provider for government sector services and is preparing to launch its retail offering in the Kingdom, unlocking significant avenues for growth.

This transaction marks Jadwa’s fifth investment under its Jadwa GCC Diversified Private Equity Fund, launched in late 2024. It follows the fund’s recent landmark acquisition of a majority stake in Makhazen Alenaya, a market leader in Saudi Arabia’s beauty and personal care retail sector, highlighting Jadwa’s active pipeline across high-growth verticals.

Tariq Al-Sudairy, Managing Director and CEO of Jadwa Investment, commented: “PetroApp presents a compelling investment opportunity, supported by a robust technology infrastructure and strong network effects. The investment aligns with our fund’s strategy of backing ambitious management teams leading high-growth, scalable businesses across a diversified range of promising sectors.”

Elie El-Khoury, Head of Private Equity at Jadwa Investment, added: “PetroApp’s impactful solution reflects the kind of innovation that supports Vision 2030’s broader shift toward digitizing critical sectors across the Kingdom. This is further reflected in PetroApp’s recent accreditation as a qualified service provider by EXPRO.”

Abdullah Al Kasabi, Chairman of PetroApp and CEO of RZM Investment, emphasized the significance of this investment round, describing it as a turning point for the company. He stated: “Back in 2020, we saw in PetroApp a promising model that blends innovation with operational efficiency in serving both fuel stations and corporate clients. Our decision to invest was driven by a clear conviction in the company’s vision and its strong potential to deliver sustainable growth. Today, we are proud to welcome Jadwa Investment and Bunat Ventures. This marks a defining milestone in PetroApp’s institutional journey and supports our ambition to list on the Saudi Exchange’s Main Market.”

Abdulaziz Al Senan, Co-Founder and CEO of PetroApp, expressed his enthusiasm about the deal, saying: “We are excited to embark on this partnership at a pivotal stage in PetroApp’s journey. Jadwa’s institutional expertise will be critical in strengthening our foundation, accelerating growth, and expanding our leadership in Saudi Arabia and beyond. Together, we remain committed to setting new benchmarks in fuel and fleet management innovation, aligning with our customers’ evolving expectations and the broader objectives of Saudi Vision 2030.”

About Jadwa Investment

Jadwa Investment is a Riyadh-headquartered investment management and advisory firm with more than SAR 100 billion (USD 30 billion) in client assets across public equity, private equity, real estate, private credit, fixed income, and money market investments. Its clients include government-related entities, local and international institutional investors, prominent family offices, and high-net-worth individuals.

 

Jadwa Investment is licensed by the Capital Market Authority of Saudi Arabia (CMA) as a capital market institution, with registration number 06034-37.



Contacts

Randa Khair

+966 11 279-1111

media@jadwa.com

PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001

TOKYO - Friday, 27. June 2025


(BUSINESS WIRE) -- PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor.


“We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in humans as well. Our preclinical animal models (LDL-R KO mice; HoFH model, and high-fat diets induced MASH model mice) have shown that PRD001 lowers blood and liver lipids and suppresses the progression of fatty liver and atherosclerosis with no adverse events. PRD001 has the potential to be the first-in-class effective and safe oral therapy for HoFH patients suffering from no or extremely low LDL receptor activity.”


This FIH Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and the signs of early efficacy (LDL-C lowing effect, and liver fat quantitative value using MRI-PDFF) of PRD001 in adult healthy volunteers. More information can be found at NCT07034183.


About PRD001


PRD001 is a first-in-class, orally available small molecule SOAT2-selective inhibitor. It uniquely controls three key pathways of lipid metabolism; cholesterol synthesis in the liver, cholesterol absorption in the small intestine, and uptake of blood LDL-C with a single drug, leading to a potent reduction in a blood LDL-C level independent of the LDL receptor.


This research and development is supported by Japan Agency for Medical Research and Development (AMED) under Strengthening Program for Pharmaceutical Startup Ecosystem (Project title: " Development of First-in-class oral lipid metabolism regulator PRD001 and POC obtained for lipid metabolism disorder ").


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250627513859/en/



Permalink

https://www.aetoswire.com/en/news/2706202547634


Contacts

PRD Therapeutics, Inc.

info[at]prdtherapeutics.com (Please replace [at] with @)

Logo Established for the “Japan Creator Support Fund” to Support the Global Success of Japan’s Next-Generation Creators and Artists

  TOKYO - Monday, 30. June 2025 AETOSWire 



English-Language Global Website Launches on Monday, June 30, 2025


(BUSINESS WIRE)--The Japan Arts Council (President: Mariko Hasegawa), with funding from the Agency for Cultural Affairs, has established the Japan Creator Support Fund to support projects nurturing Japan’s diverse creators and artists, and to support cultural facilities’ function enhancement. We are pleased to announce that the logo for the Fund has been established and that the English-language global website, which is promoting this project overseas, has been officially launched on Monday, June 30, 2025. A promotional video for international audiences is also now available on the website.


About the Japan Creator Support Fund


The Japan Creator Support Fund was established within the Japan Arts Council through the supplementary budget for FY2023 by the Agency for Cultural Affairs to support initiatives for Japan-based creators and artists, and to support cultural facilities’ function enhancement. Leveraging this Fund, “Support Programs for Creator Development & Cultural Facilities Function Enhancement” has been implemented since FY2024, where 42 projects were selected, supporting a wide range of creative genres, including manga, animation, games, performing arts, contemporary art, and traditional performing arts. It aims to foster the global success of over 600 emerging Japanese creators and artists. Additionally, the “Creator Support Program (Program Development & Implementation)” was newly established through the FY2024 supplementary budget. Furthermore, we will promote the “Japan Creator Support Fund for Entertainment, International Outreach Program (Long-Term Projects)” using subsidies allocated under the FY2024 supplementary budget by the Ministry of Economy, Trade and Industry (METI). (For details on each initiative under the Fund, please refer to the attached appendix.)


Logo Established -- Inspired by the “Plane”


A new logo has been established using the motif of a “plane.” In geometry, a plane is a flat surface that extends infinitely. The design concept envisions Japanese creators, artists, and cultural arts boldly crossing borders and venturing out into the world. The plane evokes a sense of limitless expansion in all directions and represents the spread of new creativity originating in Japan.


In addition to the main logo for the Fund as a whole, individual logos were also created for the Fund’s four support programs:


The Creator & Artist Development Support Program [FOR CREATORS]

The Support Program for Cultural Facilities Function Enhancement [FOR CULTURAL FACILITIES]

The Creator Support Program (Program Development & Implementation) [FOR CREATOR DEVELOPMENT]

The Japan Creator Support Fund for Entertainment, International Outreach Program (Long-Term Projects) funded by METI [FOR ENTERTAINMENT]

Global Website Launched


The website provides an overview of the Fund, including the four support programs offered and the projects selected under each category. Each project page features links to each project’s dedicated website and social media accounts, as well as information on participating creators and advisors. A promotional video about the fund is also available on the website. In addition, the site will be updated as needed with information on the progress of each project. It will also share details on upcoming exhibitions, performances, and other events held not only in Japan but internationally as well. The website is available in both English and Japanese.


Launch Date: Monday, June 30, 2025, 15:00.

URL: https://creator.ntj.jac.go.jp/en/


Mid-Term Report Meeting for the “Support Programs for Creator Development & Cultural Facilities Function Enhancement”


On Thursday, June 5, 2025, the Japan Arts Council held a mid-term report meeting for the “Support Programs for Creator Development & Cultural Facilities Function Enhancement.” Representatives from eight of the 42 selected projects presented activity reports, followed by a roundtable discussion featuring seven up-and-coming Japanese creators active across various genres. The event concluded with a networking session to encourage future collaboration.


Date & Time: Thursday, June 5, 2025, 3:00 pm - 6:25 pm

Venue: 3rd Floor Auditorium, Ministry of Education, Culture, Sports, Science and Technology (MEXT)


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250627404244/en/



Permalink

https://www.aetoswire.com/en/news/3006202547642


Contacts

For press inquiries regarding the Fund:

Japan Creator Support Fund Secretariat, Japan Arts Council

TEL: +81-50-1754-5909

E-mail: kiban-kikin@ntj.jac.go.jp


For press inquiries regarding logo and website:

Japan Creator Support Fund PR Office

Contact: Tsuji, Hirooka

TEL: +81-3-6260-4855

E-mail: bunka-creator-pr@kyodo-pr.co.jp


 

Raxio Côte d’Ivoire and ARTCI Sign Strategic MoU to Host Nation’s Third PoP for the National Internet Exchange (3rd CIVIX PoP)

  Landmark partnership to enhance Côte d’Ivoire’s digital infrastructure and connectivity landscape


(BUSINESS WIRE) -- Raxio Côte d’Ivoire is proud to announce the signing of a strategic Memorandum of Understanding (MoU) with the Autorité de Régulation des Télécommunications de Côte d’Ivoire (ARTCI), marking a major milestone in the advancement of the country’s digital infrastructure.

The agreement enables the colocation of the third national Point of Presence (PoP), known as CIVIX, within Raxio’s Tier III-certified, carrier-neutral data centre in Grand Bassam inside the technology Park of the free zone VITIB, the first of its kind in the nation. This partnership represents a critical step forward in Côte d’Ivoire’s ongoing digital transformation.

The newly deployed IXP will:

  • Ensure the resilience and growth of the local traffic exchanges
  • Enhance local traffic exchange and reduce latency
  • Improve digital resilience and national data sovereignty
  • Create new opportunities to attract global content providers and additional IXPs
  • Empower startups, internet service providers (ISPs), AI initiatives, and the broader tech ecosystem

The signing ceremony was led by the CEOs of both ARTCI and Raxio Côte d’Ivoire, reinforcing the shared commitment to building a more efficient, secure, and high-performing internet infrastructure in the region.

“This partnership brings additional value to our national and regional digital ecosystem,” said Robert Skjodt, CEO of Raxio Côte d’Ivoire. “We are honoured to support Côte d’Ivoire’s national digital strategy and help create an environment where local innovation, connectivity, and economic growth can flourish.”

“The deployment of this new IXP within a world-class facility like Raxio’s data centre is a key step toward achieving our vision of digital sovereignty and excellence,” added Lakoun Ouattara, CEO of ARTCI.

By localising internet traffic exchange, this initiative reduces reliance on international bandwidth, increase the availability of local content and caching servers to ensure business continuity, strengthens cybersecurity posture, and enhances the quality of service for users and businesses alike.

This milestone further underscores Raxio’s mission to empower West Africa’s digital future by providing critical infrastructure that supports regulatory priorities, private sector growth, and the digital ambitions of the region.


About Raxio

Raxio Group is Africa’s leading carrier-neutral Tier III data centre operator. We are dedicated to delivering world-class co-location and connectivity services with a commitment to supporting Africa's digital transformation through the provision of state-of-the-art efficient, reliable and sustainable data infrastructure solutions that support and catalyse economic growth and digital inclusion across the continent. Raxio Group now has operational facilities in Uganda, Ethiopia Mozambique, and the Democratic Republic of Congo, and will soon be operational in Côte d’Ivoire, Tanzania, and Angola. We are constantly expanding our footprint and are on track to build several new facilities over the coming years, establishing a network of interconnected data centres servicing the active and latent demand across the African continent.


About ARTCI

The Autorité de Régulation des Télécommunications de Côte d’Ivoire (ARTCI) is the national regulatory authority for telecommunications and ICT services, driving innovation, development, and regulation to enable digital inclusion and competitiveness across Côte d’Ivoire.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250626829454/en/



Permalink

https://www.aetoswire.com/en/news/3006202547652


Contacts

Tilson Pinto

Axicom for Raxio

tilson.pinto@axicom.com


 

Saturday, June 28, 2025

Flutterwave Named to TIME100 Most Influential Companies List for Second Time, Highlighting Global Payments Influence

SAN FRANSCISCO - Friday, 27. June 2025 

Africa’s leading payments technology company returns to this global list after its 2021 debut.

(BUSINESS WIRE) -- Flutterwave, Africa’s leading payment technology company, has been named among the TIME100 Most Influential Companies List of 2025. This marks the second time the company has received this prestigious global honor. Flutterwave joins global leaders such as Amazon, Berkshire Hathaway, Netflix, OpenAI, Universal Music Group, and others in the list’s TITANS category.

TIME reveals the fifth-annual TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world today. To assemble the list, TIME solicited nominations across sectors, and polled its global network of contributors and correspondents, as well as outside experts. Then TIME editors evaluated each on key factors, including impact, innovation, ambition, and success. The result is a diverse group of 105 businesses helping chart an essential path forward.

Founded in 2016, Flutterwave was first included on the TIME100 list in 2021. This followed a historic campaign that helped thousands of businesses impacted by the COVID-19 pandemic to sell online. Its 2025 return testifies to the company’s ongoing influence as a fintech leader, transforming payments across Africa and beyond.

The company has remained committed to connecting Africa through seamless payments. It empowers individuals and businesses to thrive in the digital economy. Today, its solutions power growth across diverse sectors. These include cross-border remittance, e-commerce, travel, payroll, and hospitality.

Flutterwave Founder and CEO, Olugbenga ‘GB’ Agboola, commented on the recognition:

“Being recognized by TIME once again is a true honor. It's a testament to our team’s incredible work. We’ve moved from building infrastructure to enabling global-scale solutions. Flutterwave today isn't just powering payments; we’re shaping Africa's financial future and connecting the continent to the world.”

In the past year, Flutterwave significantly expanded its global presence. The company now has technology reach in over 34 African countries. Nearly fifty percent of its customers received payments in new markets in 2024. Additionally, it launched operations in new markets such as Bahrain, Turkey, and Saudi Arabia for a leading global ride-hailing giant to expand in those countries. This positions Flutterwave as one of the few African fintech companies with such extensive technology reach.

Additionally, the company’s flagship remittance product, SendApp by Flutterwave, has scaled rapidly across the US, UK, and the EU. It creates faster, more affordable ways for Africans in the diaspora to send money to family and friends back home. Notably, Send App received 20 additional licenses in the US, now holding 34 such licenses across the country. This, combined with partnerships, gave the brand near-complete US coverage. The company also built a strengthened executive team. It recently introduced a focused growth strategy centered on profitability and continued market penetration and expansion.

This TIME’s 2025 list follows a wave of recent global and regional accolades. Notably, Flutterwave ranked first on Fast Company’s 2024 Most Innovative Companies list for Europe, the Middle East, and Africa. Earlier this year, it was recognized for the second consecutive year in the FXC Top 100 Cross-Border Payment Companies.

See the full list here: https://time.com/collections/time100-companies-2025/

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250626991288/en/

Permalink
https://www.aetoswire.com/en/news/2706202547605

Contacts

For additional information on Flutterwave or interview requests, please contact Hudson Sandler at flutterwave@hudsonsandler.com

CB Insights Unveils Industry's First AI Agent Workforce for M&A, Partnerships, Competitive Intelligence, Deal Sourcing, GTM, and More

  NEW YORK - Friday, 27. June 2025 AETOSWire  



Purpose-built agents work around the clock to deliver external intelligence that transforms how enterprises make strategic decisions


(BUSINESS WIRE) -- CB Insights, the leading provider of predictive market intelligence, today announced the launch of its Team of Agents – the industry's first comprehensive AI agent workforce designed specifically to enable business leaders with always-on market intelligence for strategic decision-making. CB Insights’ growing team of agents starts with 11 specialized agents that work continuously to uncover insights, translate proprietary data into action, and accelerate smart decisions by providing the external intelligence layer that enterprises need to compete effectively across business development, investments, partnerships, GTM, and competitive intelligence.


While generic AI assistants struggle with business context and lack reliable external data, CB Insights' Team of Agents delivers validated intelligence and data science on over 10 million companies and 1,500 tech markets through purpose-built specialists that understand the nuanced requirements of strategic business functions.


Enterprise clients are already hiring CB Insights’ Team of Agents to streamline their workflows and accelerate decision-making across research, diligence, briefings, and more – saving months of work.


"The Scouting Report Agent is amazing – it's a huge time saver and lets us respond quickly with enough insight to get back to a client or be dangerous with," said Bethany Boutin, Business & Market Intelligence Lead: Commercial Solutions + Digital at Evernorth Health Services, a subsidiary of The Cigna Group.


"Most AI agents today are generalists trying to do everything – but when it comes to strategic decisions, you need specialists who understand your business context and have access to reliable external intelligence," said Manlio Carrelli, CEO of CB Insights. "Our Team of Agents represents the evolution from generic AI assistants to purpose-built intelligence operatives. They work around the clock on your behalf, each one an expert in their domain, all powered by our double-verified Business Graph and data science on the world's companies and markets – insights and data that are not available on ChatGPT, the Internet, or in any other agent."


Addressing the External Intelligence Gap


While most enterprise strategic decisions require external market intelligence about competitors, markets, and potential partners, existing AI tools often lack the specialized context and validated data necessary for high-stakes business decisions. CB Insights' growing Team of Agents solves this, starting with 11 specialized agents that deliver:


Acquisition Hunter: Identifies strategic acquisition targets and early-stage disruptors before competitors notice them


Business Relationship Analyst: Maps customer, vendor, and partner relationships to reveal strategic insights


ChatCBI: Serves as an AI-to-AI interface, allowing enterprises to integrate CB Insights intelligence directly into their existing AI workflows


Commercial Due Diligence Accelerator: Reduces due diligence timelines from weeks to hours with automated expert interviews and risk assessments


Competitive Sentinel: Monitors what competitors are buying, building, and investing in before it appears in financials


Deep Analyst: Generates comprehensive research reports and market analyses in hours instead of weeks


Earnings Analyst: Delivers CEO-ready competitive intelligence within hours of earnings calls


Partner and New Business Finder: Detects high-value partnership and sales opportunities using funding and competitive signals


Personal Briefing: Scours global news to surface personalized growth opportunities and competitive threats


Sales Account Planner: Accelerates rep ramp-up with deep account understanding and tailored pitch strategies


Scouting Report: Generates analyst-grade SWOT analyses on any private company on command


The agents listed are not exhaustive and CB Insights’ clients can create their own with Microsoft Copilot, MCP, and soon directly in ChatCBI.


Agents Powered by the World's Most Comprehensive Business Graph


Unlike AI agents that rely on public web data or limited datasets, CB Insights' Team of Agents operates on the proprietary Business Graph – a continuously validated dataset with patented data science covering management teams, funding rounds, partnerships, deals, earnings calls, hiring patterns, patents, and more across global business activity.


"The quality of AI output depends entirely on the quality of data input," said Carrelli. "Our agents don't just scrape the web – they work with double-verified intelligence based on proprietary information collected from companies and their customers directly, unique datasets like their commercial relationships, and proprietary data science that scores future potential. This means when our Competitive Sentinel tells you a rival is planning a major acquisition, or when our Acquisition Hunter identifies a strategic target, you can make decisions with confidence."


Designed for Enterprise Integration


The Team of Agents operates across multiple platforms where strategic work happens:


Native integration with CB Insights' Strategy Terminal for comprehensive market intelligence workflows


Microsoft 365 Copilot integration for seamless incorporation into existing productivity tools


Model Context Protocol (MCP) compatibility for any MCP-compatible AI agent to tap into CB Insights' datasets and tools – including ChatCBI – without a single line of code


API and custom solutions for embedding intelligence into enterprise applications and workflows


CB Insights’ forward-deployed strategists work with you to automate your research and strategy flows with custom agents


"We're not asking enterprises to change how they work – we're making their existing workflows dramatically more intelligent," said Carrelli. "Whether you're in Excel building a market model, in PowerPoint preparing for a board meeting, or doing deep work inside the CB Insights terminal, our agents provide the external intelligence you need exactly when and where you need it."


Availability and Pricing


CB Insights' Team of Agents is available immediately to enterprise customers through flexible deployment options. Individual agents can be deployed for specific use cases, or enterprises can access the full team for comprehensive market intelligence automation.


For more information about CB Insights' Team of Agents and to request a demonstration, visit www.cbinsights.com/team-of-agents.


About CB Insights


Headquartered in New York City, CB Insights is the leading provider of AI for market intelligence. The company aggregates, validates, and analyzes hard-to-find private and public company data. Its powerful AI tells users what it all means to them personally. The world's smartest companies rely on CB Insights to focus on the right markets, stay ahead of competitors, and identify the right targets for sales, partnership, or acquisition. Visit www.cbinsights.com for more information.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250626444055/en/



Permalink

https://www.aetoswire.com/en/news/2706202547607


Contacts

CB Insights

jason.saltzman@cbinsights.com


 

Intelsat Partners with Whitaker Peace & Development Initiative to Expand Access to Education in East Africa

 Satellite-powered connectivity will support enhanced online education in conflict-affected regions in South Sudan and Uganda


 


(BUSINESS WIRE)--Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks, announced today a groundbreaking partnership with Academy Award-winning actor and humanitarian Forest Whitaker’s nonprofit, the Whitaker Peace & Development Initiative (WPDI), to revolutionize access to education in conflict-affected regions across Africa. The collaboration will deliver for the first time high-speed internet connectivity to WPDI’s Community Learning Centers in South Sudan and Uganda, creating digital bridges to education for thousands of young people in areas where infrastructure has been insufficient or compromised.


Intelsat will equip 10 centers—seven in South Sudan and three in Uganda—with satellite connectivity. Over the course of this three-year partnership, Intelsat will provide equipment, managed connectivity services, installation, and ongoing technical support. This unprecedented effort will bring reliable internet access to communities where traditional connectivity infrastructure is inadequate for modern online education.


“Education is the foundation for peace,” said Forest Whitaker. “At WPDI, we use technology as a conduit to opportunity—bringing knowledge to young people whose lives have been upended by violence and political unrest. With the right tools, youths can reclaim their futures to become powerful agents of peace in their communities.”


The initiative comes at a critical time, as digital inequality continues to widen globally. According to the International Telecommunication Union, a mere 19% of people in the least developed nations, like South Sudan and Uganda, use the internet. In areas directly affected by conflict, these numbers drop even further, creating significant barriers to education and opportunity for vulnerable populations. By improving digital access, Intelsat and WPDI are providing learning center trainees with the resources they need to become drivers of positive change in their community and beyond. Graduates of WPDI programs have gone on to become community leaders, educators, and advocates, exemplified by individuals like Benson Lugwar, a former child soldier who is now an elected official and radio host in Uganda.


“At Intelsat, we are great believers in the power of connectivity to promote education and sustainable development around the world,” said Dave Wajsgras, CEO of Intelsat. “Forest Whitaker and WPDI’s efforts represent exactly the kind of transformative work that satellite communications can enable. We’re proud to support WPDI’s efforts to bring young people together, close the digital divide, and create pathways to prosperity in communities that need it most.”


The satellite-powered connectivity will enable WPDI to significantly expand its educational offerings, providing access to digital resources, online courses, and virtual exchange programs that were previously impossible in these remote locations. Students will gain critical digital literacy skills alongside WPDI’s established curriculum in conflict resolution, entrepreneurship, and community development.


About WPDI


The Whitaker Peace & Development Initiative (WPDI) is a non-governmental organization with an international scope and reach, committed to fostering peace and resilience by disseminating skills and promoting climate-sensitive and sustainable development in countries and places affected by violence, poverty, environmental disruption, and marginalization. In Africa, Europe, as well as Latin and North America, WPDI develops a wide range of programs aimed at training and supporting underprivileged individuals and groups, with a particular focus on youth and women, enabling them to become empowered as mediators, educators, entrepreneurs, and leaders, fostering positive transformation within their communities and beyond. To achieve its objectives, WPDI works with the communities to design and implement integrated programs in the four areas of Peacebuilding, Livelihood, Health and Well-being, and Sports. WPDI was founded in 2012 by the artist, social activist, and UNESCO Special Envoy for Peace, Forest Whitaker. www.wpdi.org


About Intelsat


Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.


Follow Us on Social Media:

Twitter/X

LinkedIn

Instagram

YouTube


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250625237871/en/



Permalink

https://www.aetoswire.com/en/news/2606202547564


Contacts

Media Contact:

Melissa Longo - melissa.longo@intelsat.com; +1 240-308-1881

Friday, June 27, 2025

Kinaxis and Ottawa Senators Renew Partnership, Uniting National Capital Region


 OTTAWA, Ontario -

Bold partnership focuses on elevating community impact and brand presence


(BUSINESS WIRE) -- Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is proud to announce a renewed three-year partnership with the Ottawa Senators and their AHL affiliate, the Belleville Senators. This collaboration is designed to amplify Kinaxis’ brand visibility, deepen community roots, and create unforgettable experiences for customers, prospects, and employees.


As two proud Ottawa-based organizations, Kinaxis and the Senators will come together again to celebrate local talent, foster youth development, and drive meaningful community engagement. The partnership will also spotlight the Kinaxis brand across high-visibility platforms—including center ice at Canadian Tire Centre, LED rings, and digital dashboards during home and away games—ensuring a powerful presence throughout the NHL season.


“At Kinaxis, we believe in the power of community and the importance of showing up where it matters most,” said Megan Paterson, chief operating officer at Kinaxis. “This partnership is more than just branding - it’s about connecting with people, supporting local causes, and creating a culture of pride and purpose for our employees, our customers, and the broader Ottawa community.”


As part of its commitment to community impact, Kinaxis will support two of the Senators’ most meaningful philanthropic initiatives:


Together We Ignite Hope Telethon – A region-wide fundraising campaign that supports youth-focused charities and grassroots programs across the National Capital Region. Funds raised go toward mental health services, education access, food security, and recreational opportunities for underserved youth.


Ottawa Senators Gala – The team’s premier annual fundraising event, bringing together business and community leaders to raise funds for youth empowerment through sport, education, and wellness. Kinaxis’ involvement helps expand the reach and impact of these programs, ensuring more young people have access to the tools and support they need to thrive.


These initiatives align with Kinaxis’ broader social impact strategy, which includes long-standing partnerships with organizations such as Interval House of Ottawa (supporting women and children fleeing violence), Quickstart Early Intervention for Autism, and The Ellen MacArthur Foundation (advancing circular economy education). Kinaxis also invests in the next generation of talent through its award-winning co-op program and has been recognized as one of Canada’s Top 100 Employers and a Top Employer for Young People.


The renewed partnership also brings employees, customers, and prospects closer to the action, with exclusive access to Senators games, community skate events at Canadian Tire Centre, and behind-the-scenes experiences that foster lasting connections within the community.


“This collaboration is a celebration of shared values—excellence, innovation, and community,” said Cyril Leeder, president and CEO of the Ottawa Senators. “Fresh off a playoff run that ignited our fans and our community, we’re excited to have Kinaxis – a leader in Ottawa’s tech community – in our Senators family to further the momentum from last season and look forward to continuing to build something truly special together.”


As Kinaxis continues to grow its global footprint, this partnership reinforces its identity as a purpose-driven brand rooted in community, innovation, and Canadian pride. For more information about Kinaxis visit kinaxis.com.


About Kinaxis

Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.


About the Ottawa Senators:

One of seven NHL franchises based in Canada, the Ottawa Senators returned to the league in 1992 following a 58-year absence. Ottawa won 11 Stanley Cups during its original reign from 1903 to 1934. The modern-day Senators have captured four division titles, a Presidents’ Trophy in 2002-03 and reached the Stanley Cup Final in 2007. Since 1992, the Senators together with its charitable foundation, alumni, partners and fans have contributed more than $100 million to community initiatives in the Ottawa-Gatineau Region. The team was purchased by Michael Andlauer in September of 2023, ushering in a new era and vision for the franchise.


Visit the Senators website: www.ottawasenators.com

Engage with the Senators on Twitter: @Senators

Like the Senators on Facebook: www.facebook.com/ottawasenators

Follow the Senators on Instagram: senators


Source: Kinaxis Inc.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250626377445/en/



Permalink

https://www.aetoswire.com/en/news/2706202547608


Contacts

Media Relations:


Ian Mendes | Ottawa Senators

mendesi@ottawasenators.com


Erin Boyle | Kinaxis

eboyle@kinaxis.com

+1 519-574-4065

Lenovo Named a Major Player in IDC MarketScape for Hybrid IT Infrastructure Consulting and Integration Services

 


MORRISVILLE, N.C. 

(BUSINESS WIRE) -- Lenovo has been positioned in the Major Players Category in the IDC MarketScape: Worldwide Hybrid IT Infrastructure Consulting and Integration Services 2025 Vendor Assessment.*


According to the report, “Lenovo has significantly invested in its portfolio globally over the past three or more years, with a focus on continuing to build services that accelerate its customers' hybrid cloud, multicloud, and AI cloud initiatives.”


And: “Lenovo's investments in the company's tools, processes, and methodologies were reviewed positively among customers and study respondents, highlighting the ability of the company to improve digital infrastructure and increase visibility of infrastructure and enabling its customers' business agility.”


Driving Business Impact


Enterprises are rapidly adopting hybrid IT models to stay competitive in an AI-driven economy. Lenovo regards its recognition in the IDC MarketScape as a reflection of its unique ability to deliver scalable, AI-optimized hybrid cloud solutions that are redefining business operations.


“Enterprises are seeking clarity when it comes to AI adoption and their high-performance computing and cloud strategies,” said Linda Yao, Vice President of Hybrid Cloud and AI Solutions, Lenovo. “That’s why we’ve focused heavily on building end-to-end solutions – from advisory to design, deployment, and ongoing support – to help our customers achieve measurable business outcomes aligned with their IT infrastructure needs, as well as their AI strategies and business goals.”


Comprehensive Services Portfolio


Lenovo helps organizations make better use of their data, moving systems to the cloud, and simplifying complex infrastructure. Its services include planning and guidance for cloud, data, and AI projects. These offerings are standardized using Lenovo’s proven five-stage methodology with each phase underpinned by services like Lenovo AI Fast Start.


The IDC MarketScape also highlighted positive sentiment from Lenovo customers: “The goals that we had were achieved when working with (Lenovo); we are able to have their support at all times, and we are operational and functional and more efficient because of their services.”


And: “Lenovo offered significant improvement in all negotiated areas of our business and did exactly what we expected within our price and agreed timing.”


Additional Information


Learn how Lenovo’s solutions support faster business outcomes from AI adoption, with a focus on hybrid cloud optimization.


Read a complimentary excerpt of the IDC MarketScape report.


*IDC MarketScape: Worldwide Hybrid IT Infrastructure Consulting and Integration Services 2025 Vendor Assessment (Doc # US53312825, April 2025)


About IDC MarketScape


IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.


About Lenovo


Lenovo is a US$69 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250626824135/en/



Permalink

https://www.aetoswire.com/en/news/2606202547594


Contacts

Zeno Group for Lenovo: lenovossg@zenogroup.com


 

ExaGrid Expands Partnership with Cohesity with New Certified Integrations, Enabling Seamless Backup Storage for Both Cohesity NetBackup and DataProtect Customers

 Customers can now archive Cohesity data to ExaGrid to help reduce storage costs


 


(BUSINESS WIRE)--ExaGrid®, the world’s largest independent backup storage vendor, has announced that it will be an archive storage target for Cohesity DataProtect with its Tiered Backup Storage product line.


Today, ExaGrid supports Cohesity NetBackup with 9 certified integrations. As Cohesity continues to support both NetBackup and DataProtect customers, ExaGrid’s Tiered Backup Storage appliances will continue to work as an archive storage target for all Cohesity customers.


ExaGrid’s support for Cohesity is expected to be Generally Available (GA) in the first half of 2026.


“We’re excited to support Cohesity, including both their NetBackup and DataProtect customers,” said Bill Andrews, President and CEO of ExaGrid. “With customers in over 80 countries, we’re seeing growing interest in Cohesity, and we want to ensure that their investment in ExaGrid remains protected during that transition.”


ExaGrid Tiered Backup Storage features a unique architecture with a front-end Landing Zone for fast archiving and restores, and a secure Repository Tier for cost-efficient, deduplicated storage. The system scales up to 6PB in a single deployment—the largest of its kind with built-in deduplication. Over the past three years, ExaGrid has earned more industry awards for backup storage than any other vendor.


“Customers rely on us to secure hundreds of exabytes of critical customer data across their IT landscape. Cohesity meets customers where they are with our broad support for data sources and storage targets,” said Vasu Murthy, Chief Product Officer, Cohesity. “We’re proud to partner with ExaGrid to support our joint customers seeking a tiered archival storage solution.”


About ExaGrid


ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, scale-out architecture, and comprehensive security features. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The Repository Tier offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and planned product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier (tiered air gap), delayed deletes, and immutable objects to recover from ransomware attacks.


ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, India, Israel, Italy, Japan, Mexico, Nordics, Poland, Portugal, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.


Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup storage in our customer success stories. ExaGrid is proud of our +81 NPS score!


ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250626334245/en/



Permalink

https://www.aetoswire.com/en/news/2606202547591


Contacts

Media:

Mary Domenichelli

ExaGrid

mdomenichelli@exagrid.com

Rigaku Expands Production Facilities for the Semiconductor Market

 50% increase in production capacity marks a speedy response to global markets


(BUSINESS WIRE) -- Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) has increased its capacity for production of semiconductor process control instruments at its own plant in Takatsuki, Osaka Prefecture and at the facilities of a partner company* in Nirasaki, Yamanashi Prefecture.

* 6th factory of Nippo Precision Co., Ltd.


Against a background of rapidly growing adoption of AI semiconductors, the market for semiconductor manufacturing and inspection equipment is expanding rapidly. Accelerating growth in semiconductor performance and density is making accurate measurement and evaluation of complex nanoscale structures, such as thin-profile, multi-layer designs, 3D memory and 3D transistors, indispensable.


With the current expansion in production capacity, Rigaku has doubled the floor space of its assembly and inspection areas. The recent completion of a production facility in Yamanashi Prefecture boosts production capacity for core components such as X-ray generators and detectors. In tandem, overall capacity for production of semiconductor process control instruments is expected to be 50% higher in Q4 of FY2025 than in the same period of the previous fiscal year, based on unit count. Rigaku’s policy is to continue expanding equipment in response to demand, further increasing capacity by 50% compared to Q4 of FY2024 by 2027.


Through these efforts, Rigaku expects to achieve dramatic growth in sales of semiconductor process control equipment in Q4 FY2025, fulfilling its plan to reach 20% growth on a full-year basis.


Markus Kuhn, General Manager of the Semiconductor Metrology Division, offered the following remarks:

This reinforcement of our production framework marks an important milestone for Rigaku’s global strategy. Our technology is responding to industry needs for high-precision, nanoscale shape, thickness and composition evaluation, required for next-generation devices such as 3D-NAND and GAA transistors. The reliability and reproducibility of our platforms earn high respect internationally. By expanding our production capacity, we can dramatically improve our on-time delivery capability, strengthening our seamless support systems from development to production. Rigaku will continue to support customers’ leading-edge process development in terms of both technical innovation and supply infrastructure, further buttressing our competitive edge in the global market.


Related press releases

Published May 28, 2025: Rigaku Completes New Building at Yamanashi Plant-Dramatic 2.7-fold increase in floor space to serve global demand-


About the Rigaku Group

Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”

For details, please visit rigaku-holdings.com/english


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250626657793/en/



Permalink

https://www.aetoswire.com/en/news/2606202547599


Contacts

Press Contact:

Sawa Himeno

Head of Communications Dept., Rigaku Holdings Corporation

prad@rigaku.co.jp

Tel: +81 90 6331 9843